Tasonermin

Beromun · ATC code L03AX11

Key facts
Active substance: Tasonermin
Drug class: Cytovir-3
ATC code: L03AX11
Authorisation: centrally authorised across the EU (EMA)
Dosage forms: Beromun 1 mg powder for solution for infusion
Marketing authorisation holder: Belpharma s.a.
Information as of: 2026-10-27

Key facts

Tasonermin is recombinant tumour necrosis factor alpha used with melphalan via isolated limb perfusion to treat soft tissue sarcoma of the limbs.

What it is used for

Adults with irresectable soft tissue sarcoma of the limbs
As an adjunct to surgery to prevent or delay amputation, or in the palliative situation
Only in combination with melphalan via mild hyperthermic isolated limb perfusion (ILP)

Dosing

Only in specialised centres with experienced teams and an intensive care unit available
Upper limb: 3 mg total dose by ILP
Lower limb: 4 mg total dose by ILP
Melphalan dose based on limb volume, to a maximum of 150 mg
Administered only if leakage into the systemic circulation is less than 10 %

Contraindications

Hypersensitivity to the active substance or any excipient
Significant cardiovascular disease (e.g. heart failure NYHA II–IV, severe angina, recent myocardial infarction, venous thrombosis)
Severe pulmonary dysfunction, recent or active peptic ulcer, severe ascites
Significant haematological or renal dysfunction
Pregnancy; breast-feeding within 7 days of ILP

Important warnings

Must not be administered systemically
Continuous monitoring for leakage into the systemic circulation
Blood pressure, urine output and ECG monitoring for the first 24 to 48 hours after ILP
Fever and influenza-like symptoms; prophylaxis e.g. with paracetamol before ILP

Side effects

Most frequent: fever, nausea, vomiting, fatigue, arrhythmia, chills, pain, wound infection, skin reaction
Common: leukopenia, thrombocytopenia, nerve injury, cardiac failure, thrombosis, shock, hypotension, ARDS
Uncommon: sepsis, pulmonary oedema

Interactions

Combinations with cardiotoxic substances (e.g. anthracyclines) should be avoided
With interferon-gamma, the overall incidence of adverse events is increased without demonstrated added value

Pregnancy and breastfeeding

Contraindicated in pregnancy
Breast-feeding is contraindicated within 7 days of ILP

Summary of the official product information, written with AI (Claude, Anthropic) on 2026-10-28. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

Package leaflet for patients →

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

BeromunBelpharma s.a. · EMEA/H/C/000206

Source: European Medicines Agency (EMA), product information

Brand names in 3 more European countries

Iceland: Beromun
Liechtenstein: Beromun
Norway: Beromun

EMA – Article 57 product data (EU/EEA), 2026-10-28

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

European Medicines Agency. Beromun – EPAR, Product Information (OF THE TEXT Detailed information on this product is availabl). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/beromun-epar-product-information_en.pdf
Wikidata (CC0): ATC L03AX.

Editorial: Medelix editorial team · last updated 2026-10-27 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.